Home › Research › Clinical trials
Clinical Meaningfulness of Donanemab in Early Symptomatic Alzheimer Disease: Data From the Randomized Phase 3 TRAILBLAZER-ALZ 2 Trial
Atri A, Apostolova LG, Iwata A, Wessels AM, Atkins A, Lu M, Ye W, Ryan S, Doty EG. Neurology: Clinical Practice, 2026-05-13
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Donanemab, a monoclonal antibody targeting the insoluble form of β-amyloid found in plaques, significantly slows cognitive and functional decline of AD in participants with mild cognitive impairment (MCI) or mild AD-related dementia. Results Donanemab reduced the risk of progression from MCI to mild AD by 33% (hazard ratio [HR] = 0.67; 95% CI 0.52-0.87; p = 0.003) and from mild to moderate AD by 50% (HR = 0.50; 95% CI 0.33-0.78; p = 0.002). Discussion These results add to the evidence and further support clinically meaningful donanemab-mediated effects on cognition and function for patients and their caregivers and may aid communication of realistic treatment expectations and informed decision-making. Start date of recruitment: June 19, 2020. clinicaltrialsregister.eu/ctr-search/trial/2020-000077-25/results.
What this study adds
Evidence grade: Moderate
In this Phase 3 trial, donanemab reduced the risk of progression from mild cognitive impairment to mild Alzheimer's disease by 33% and from mild to moderate Alzheimer's disease by 50%. Its stated limit: Authored by manufacturer employees and consultants; several analyses are post hoc; relative risk reductions can sound larger than the underlying absolute differences; 76-week horizon; the trial excluded many typical patients.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Atri, A., Apostolova, L. G., Iwata, A., Wessels, A. M., Atkins, A., Lu, M., et al. (2026). Clinical Meaningfulness of Donanemab in Early Symptomatic Alzheimer Disease: Data From the Randomized Phase 3 TRAILBLAZER-ALZ 2 Trial. Neurology: Clinical Practice. https://doi.org/10.1212/CPJ.0000000000200621
Vancouver
Atri A, Apostolova LG, Iwata A, Wessels AM, Atkins A, Lu M, et al. Clinical Meaningfulness of Donanemab in Early Symptomatic Alzheimer Disease: Data From the Randomized Phase 3 TRAILBLAZER-ALZ 2 Trial. Neurology: Clinical Practice. 2026. doi:10.1212/CPJ.0000000000200621. PMID: 42128444.
BibTeX
@article{atri2026-42128444,
author = {Atri, A. and Apostolova, L. G. and Iwata, A. and Wessels, A. M. and Atkins, A. and Lu, M. and Ye, W. and Ryan, S. and Doty, E. G.},
title = {{Clinical Meaningfulness of Donanemab in Early Symptomatic Alzheimer Disease: Data From the Randomized Phase 3 TRAILBLAZER-ALZ 2 Trial}},
journal = {Neurology: Clinical Practice},
year = {2026},
doi = {10.1212/CPJ.0000000000200621},
pmid = {42128444},
url = {https://doi.org/10.1212/CPJ.0000000000200621}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 9 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- Donanemab, a monoclonal antibody targeting the insoluble form of β-amyloid found in plaques, significantly slows cognitive and functional decline of AD in participants with mild cognitive impairment (MCI) or mild AD-related dementia.
- Results Donanemab reduced the risk of progression from MCI to mild AD by 33% (hazard ratio [HR] = 0.67; 95% CI 0.52-0.87; p = 0.003) and from mild to moderate AD by 50% (HR = 0.50; 95% CI 0.33-0.78; p = 0.002).
- Discussion These results add to the evidence and further support clinically meaningful donanemab-mediated effects on cognition and function for patients and their caregivers and may aid communication of realistic treatment expectations and informed decision-making.
- Start date of recruitment: June 19, 2020. clinicaltrialsregister.eu/ctr-search/trial/2020-000077-25/results.
Why it matters
In this Phase 3 trial, donanemab reduced the risk of progression from mild cognitive impairment to mild Alzheimer's disease by 33% and from mild to moderate Alzheimer's disease by 50%. These results support clinically meaningful effects on cognition and function for patients with early symptomatic Alzheimer's disease.
New to this subject? Start with our plain-English guide: Registered clinical trials →
Study details
- Study designphase-3-trial
- Effect sizeHR 0.67 for MCI-to-mild-dementia progression; HR 0.50 for mild-to-moderate; HR 0.74 for progression to needing in-home support
- Evidence strengthModerate
Limitations
Authored by manufacturer employees and consultants; several analyses are post hoc; relative risk reductions can sound larger than the underlying absolute differences; 76-week horizon; the trial excluded many typical patients.
How this study scored 63/100
Published in a peer-reviewed journal, and it is a large phase 3 trial. Scored zero for sample size and studied in people because the record does not state it. We have no data on journal's citation record and free to read, so those were left out: it earned 59 of the 94 points we could judge it on, which is 63 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Neurology: Clinical Practice) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 11 / 12 | A large phase 3 trial |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 1 / 2 | Randomized (as stated in the record) |
| Times cited | 2 / 7 | Cited 6 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 3.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 5 / 6 | Cited 24.8× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 1 other studies in this library |
| Still being cited | 1 / 4 | Cited 6 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Erin Gautier Doty: h-index 15 (OpenAlex, whole career) |
| Institution's track record | 3 / 3 | Harvard University: institution h-index 3,235 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 9 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 42128444) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 59 / 94 | Scored on 18 of 20 parts. We have no data for the rest, so they are left out: 59 of the 94 points we could judge it on is 63 out of 100. |
| Total | 63 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1212/CPJ.0000000000200621
- PubMed: 42128444
- Original source →
- Free full text: PubMed Central →
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in Clinical trials from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.